

Huntington’s Disease: Detecting the Silent Progression
Huntington’s disease (HD) is a genetic neurodegenerative disorder that progressively impairs movement, cognition, and behavior. However, a recent study led by researchers at University College London reveals that subtle brain changes begin as early as 20 years before clinical motor symptoms appear. These findings could revolutionize Huntington’s prevention strategies and early treatments for Huntington’s and other neurodegenerative diseases.
Key Study Findings
- Pre-Symptomatic Brain Changes:
Subtle neurodegeneration was detected in individuals with Huntington’s gene expansion years before symptom onset, particularly in the caudate and putamen brain regions. - Biomarker Insights:
Elevated neurofilament light chain (NfL) levels, indicating neuronal injury, and decreased proenkephalin (PENK) levels, marking neurodegenerative response, were observed. - Longitudinal Analysis:
Over five years, 57 participants with Huntington’s gene expansion showed no noticeable clinical decline in cognition or movement but exhibited progressive changes in brain scans and spinal fluid biomarkers. - Mechanistic Discovery:
Somatic CAG repeat expansions in the huntingtin gene were directly linked to early brain changes, offering evidence for their role in neurodegeneration.
Implications for Future Huntington’s Prevention Trials
This groundbreaking research emphasizes the significance of early intervention. The detection of subtle biomarkers decades before clinical symptoms highlights a potential therapeutic window.
- Validation of Therapeutic Targets:
Suppressing somatic CAG repeat expansion could delay or prevent neurodegenerative changes. - Broader Impact:
Insights into HD may inform approaches for conditions like Alzheimer’s, where early intervention could be transformative. - Hope for Prevention Trials:
With treatments targeting somatic CAG expansion under development, the study offers a solid foundation for future preventative clinical trials.
The Role of Somatic CAG Expansion in Huntington’s Prevention
CAG expansions in the huntingtin gene amplify over time, accelerating neuron damage. This process was found to be measurable through blood analysis, predicting brain volume reductions and validating it as a promising therapeutic target.
Future Directions
This study paves the way for preventive approaches:
- Earlier Diagnoses: Leveraging biomarkers like NfL and PENK for pre-symptomatic detection.
- Therapeutic Development: Supporting the ongoing development of drugs aimed at mitigating somatic CAG expansions.
- Broad Neurodegenerative Applications: Exploring similar early interventions for other conditions, including Alzheimer’s and Parkinson’s.
- Join Internation Brain Health Symposium 2025 for latest updates.
More Information: Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis, Nature Medicine (2025). DOI: 10.1038/s41591-024-03424-6
more recommended stories
Brain’s High-Tech Fix for Blurry Vision During Movement
High-Tech Video Optimization in Our Brain:.
Air Pollution Hurts Brain Health in Just 4 Hours
Air Pollution Blurs the Mind, Impairs.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disorders
Urgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences Division
The High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences Division
The installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences Division
Scientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences Division
Antimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences Division
The TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences Division
The research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences Division
Only 30 prizes are awarded throughout.
Leave a Comment